Motif Bio (MTFB) Price Target Cut to GBX 106 by Analysts at Peel Hunt
Several other brokerages have also commented on MTFB. Northland Securities reaffirmed a buy rating on shares of Motif Bio in a report on Monday, February 5th. FinnCap reaffirmed a buy rating and issued a GBX 100 ($1.38) price objective on shares of Motif Bio in a report on Wednesday, November 22nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has an average rating of Buy and a consensus price target of GBX 101.50 ($1.40).
Shares of Motif Bio (LON:MTFB) opened at GBX 32.50 ($0.45) on Tuesday. Motif Bio has a fifty-two week low of GBX 23.50 ($0.32) and a fifty-two week high of GBX 51.75 ($0.71). The company has a market capitalization of $93.75 and a price-to-earnings ratio of -125.00.
About Motif Bio
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.